Evidence map›Paper›PMID 35837393›Full record

ReviewFrontiers in immunology2022

Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review.

Andrea Gramegna, Andrea Lombardi, Nicola I Lorè, Francesco Amati, Ivan Barone, Cecilia Azzarà, Daniela Cirillo, Stefano Aliberti, Andrea Gori, Francesco Blasi

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094711 (Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG in Patients With Mycobacterium Avium Complex Lung Disease), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07094711 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG in Patients With Mycobacterium Avium Complex Lung Disease (BOOST)

TypeinterventionalSponsorUniversity of VirginiaRan2026 to 2028Enrolled48ConditionsMycobacterium Avium-intracellulare Infection, Mycobacterium Infections, NontuberculousArmsMycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Comments on "PD-1 Inhibitor for DisseminatedOpen forum infectious diseases · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Andrea GramegnaDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Andrea LombardiDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Nicola I LorèEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco AmatiIRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.
Ivan BaroneDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Cecilia AzzaràDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Daniela CirilloEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Stefano AlibertiIRCCS Humanitas Research Hospital, Respiratory Unit, Milan, Italy.
Andrea GoriDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Francesco BlasiDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversity of Milan · ITHumanitas University · ITIRCCS Humanitas Research Hospital · ITIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental microorganisms capable of a wide range of infections that primarily involve the lymphatic system and the lower respiratory tract. In recent years, cases of lung infection sustained by NTM have been steadily increasing, due mainly to the ageing of the population with underlying lung disease, the enlargement of the cohort of patients undergoing immunosuppressive medications and the improvement in microbiologic diagnostic techniques. However, only a small proportion of individuals at risk ultimately develop the disease due to reasons that are not fully understood. A better understanding of the pathophysiology of NTM pulmonary disease is the key to the development of better diagnostic tools and therapeutic targets for anti-mycobacterial therapy. In this review, we cover the various types of interactions between NTM and lymphoid effectors of innate and adaptive immunity. We also give a brief look into the mechanism of immune exhaustion, a phenomenon of immune dysfunction originally reported for chronic viral infections and cancer, but recently also observed in the setting of mycobacterial diseases. We try to set the scene to postulate that a better knowledge of immune exhaustion can play a crucial role in establishing prognostic/predictive factors and enabling a broader investigation of immune-modulatory drugs in the experimental treatment of NTM pulmonary disease.

Indexed as

Lung DiseasesMycobacteriumMycobacterium Infections, NontuberculousPneumonia, BacterialHumansLymphocytesNontuberculous Mycobacteriaadaptive immunityimmune checkpoint inhibitorsimmune dysfunctionimmune exhaustionnon-tuberculous mycobacteria

Identifiers

PMID35837393
PMCPMC9273994
OpenAlexW4283661084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.